These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28709933)

  • 1. Identification of novel biomarker and therapeutic target candidates for diagnosis and treatment of follicular carcinoma.
    Lai X; Umbricht CB; Fisher K; Bishop J; Shi Q; Chen S
    J Proteomics; 2017 Aug; 166():59-67. PubMed ID: 28709933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Novel Biomarker and Therapeutic Target Candidates for Diagnosis and Treatment of Follicular Adenoma.
    Lai X; Chen S
    Cancer Genomics Proteomics; 2015; 12(6):271-81. PubMed ID: 26543076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIB-1 immunohistometry of follicular adenoma and follicular carcinoma of the thyroid gland.
    Rickert D; Mittermayer C; Lindenfelser R; Biesterfeld S
    Anal Quant Cytol Histol; 2000 Jun; 22(3):229-34. PubMed ID: 10872040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic identification of new biomarkers and application in thyroid cytology.
    Torres-Cabala C; Bibbo M; Panizo-Santos A; Barazi H; Krutzsch H; Roberts DD; Merino MJ
    Acta Cytol; 2006; 50(5):518-28. PubMed ID: 17017437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
    Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
    Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.
    Atik E; Guray M; Gunesacar R; Ozgur T; Canda T
    Indian J Cancer; 2014; 51(1):63-8. PubMed ID: 24947099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Approach to thyroid incidentaloma and follicular adenoma].
    Tajiri J
    Nihon Rinsho; 2007 Nov; 65(11):2099-105. PubMed ID: 18018577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HBME-1 and cyclin D1 as diagnostic markers for follicular thyroid carcinoma].
    Moyano L; Franco C; Carreño L; Robinson P; Sánchez G
    Rev Med Chil; 2004 Mar; 132(3):279-84. PubMed ID: 15376563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
    Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
    Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
    Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
    J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma.
    Umbricht CB; Saji M; Westra WH; Udelsman R; Zeiger MA; Sukumar S
    Cancer Res; 1997 Jun; 57(11):2144-7. PubMed ID: 9187112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APLP2, RRM2, and PRC1: New Putative Markers for the Differential Diagnosis of Thyroid Follicular Lesions.
    Castelblanco E; Zafon C; Maravall J; Gallel P; Martinez M; Capel I; Bella MR; Halperin I; Temprana J; Iglesias C; Puig-Domingo M; Robledo M; Matias-Guiu X; Mauricio D
    Thyroid; 2017 Jan; 27(1):59-66. PubMed ID: 27796194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Follicular thyroid tumor as a diagnostic and therapeutic problem].
    Król R; Heitzman M; Pawlicki J; Ziaja J; Cierpka L
    Postepy Hig Med Dosw (Online); 2004; 58():490-4. PubMed ID: 15765010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
    Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from enchondroma.
    Lai X; Chen S
    Proteomics; 2015 Jul; 15(13):2358-68. PubMed ID: 25755173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma.
    Haghpanah V; Shooshtarizadeh P; Heshmat R; Larijani B; Tavangar SM
    Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):422-5. PubMed ID: 17122639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of metabolites discriminating subtypes of thyroid cancer: Molecular profiling of FFPE samples using the GC/MS approach.
    Wojakowska A; Chekan M; Marczak Ł; Polanski K; Lange D; Pietrowska M; Widlak P
    Mol Cell Endocrinol; 2015 Dec; 417():149-57. PubMed ID: 26415588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
    Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
    APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic profiling of follicular and papillary thyroid tumors.
    Sofiadis A; Becker S; Hellman U; Hultin-Rosenberg L; Dinets A; Hulchiy M; Zedenius J; Wallin G; Foukakis T; Höög A; Auer G; Lehtiö J; Larsson C
    Eur J Endocrinol; 2012 Apr; 166(4):657-67. PubMed ID: 22275472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.